Multiple myeloma: biological and clinical significance of bone marrow plasma cell labelling index.

No abstract is available for this paper.

• Publication year

  1987

• Venue

  Haematologica

• Publication date

  1987-03-01

• Fields of study

  Biology, Medicine

• Identifiers
  PMID 3114074
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• Multiple Myeloma Plasma Cell Kinetics: Rapid and Reliable Evaluation using 5-Bromo-2-Deoxyuridine (BrdUrd) DNA Incorporation Detected by an Anti-BrdUrd Monoclonal Antibody

  1986cited by this paper
• Improved survival duration with combination chemotherapy induction for multiple myeloma: a Southwest Oncology Group Study.

  1986cited by this paper
• Prognostic factors and staging in multiple myeloma: a reappraisal.

  1986cited by this paper
• Analysis of human myeloma cell population kinetics.

  1986cited by this paper
• Serum beta2‐microglobulin: a real improvement in the management of multiple myeloma?

  1985cited by this paper
• Decreased ecto-5'nucleotidase activity of peripheral blood lymphocytes in human monoclonal gammopathies: correlation with tumor cell kinetics.

  1985cited by this paper
• Implications of kinetic heterogeneity in clinical oncology.

  1985cited by this paper
• Low plasma cell 3(H) thymidine incorporation in monoclonal gammopathy of undetermined significance (MGUS), smouldering myeloma and remission phase myeloma: a reliable indicator of patients not requiring therapy

  1984cited by this paper
• Kinetics of circulating B lymphocytes in human myeloma.

  1983cited by this paper
• Alternating combination chemotherapy and levamisole improves survival in multiple myeloma: a Southwest Oncology Group Study.

  1983cited by this paper
• Clinical, morphological, and cell kinetic differences among multiple myeloma, monoclonal gammopathy of undetermined significance, and smoldering multiple myeloma.

  1983cited by this paper
• The idiotypic specificities of lymphocytes in human monoclonal gammopathies: analysis with the fluorescence activated cell sorter.

  1983cited by this paper
• Serum beta2 microglobulin and survival duration in multiple myeloma: a simple reliable marker for staging.

  1983cited by this paper
• Human myeloma: kinetics of the remission phase.

  1982cited by this paper
• Ploidy and proliferative characteristics in monoclonal gammopathies.

  1982cited by this paper
• Monitoring of a Long Survival Myeloma Patient

  1981cited by this paper
• Timed sequential chemotherapy of cytoxan-refractory multiple myeloma with cytoxan and adriamycin based on induced tumor proliferation.

  1981cited by this paper
• Idiotypic lymphocytes in human monoclonal gammopathies.

  1981cited by this paper
• Growth kinetics of minimal tumour masses: implications for rational chemotherapy.

  1981cited by this paper
• Pretreatment tumor mass, cell kinetics, and prognosis in multiple myeloma.

  1980cited by this paper
• Idiotypic studies on myeloma B cells.

  1979cited by this paper
• Studies on the clonal origin of multiple myeloma. Use of individually specific (idiotype) antibodies to trace the oncogenic event to its earliest point of expression in B-cell differentiation

  1979cited by this paper
• Plasma cell acid phosphatase, a discriminative test for benign and malignant monoclonal gammopathies.

  1977cited by this paper
• Treatment of multiple myeloma in remission with anticancer drugs having cell cycle specific characteristics.

  1977cited by this paper
• Immunoglobulin patterns in humans over 95 years of age.

  1975cited by this paper
• Immunoglobulin synthesis and tumor kinetics of multiple myeloma.

  1973cited by this paper
• Multiple myeloma and benign monoclonal gammopathy: differentiation by immunofluorescence of lymphocytes.

  1973cited by this paper
• Kinetics of tumor growth and regression in IgG multiple myeloma.

  1972cited by this paper
• A population study on monoclonal gammapathy. Follow-up after 5 and one-half years on 64 subjects detected by electrophoresis of 6995 sera.

  1972cited by this paper

• The impact of upfront versus sequential use of bortezomib among patients with newly diagnosed multiple myeloma (MM): a joint analysis of the Singapore MM Study Group and the Korean MM Working Party for the Asian myeloma network.

  2013cites this paper
• The impact of frontline risk‐adapted strategy on the overall survival of patients with newly diagnosed multiple myeloma: an analysis of the Singapore multiple myeloma study group

  2012cites this paper
• S- phase plasma cells A new staging system for multiple myeloma based on the number of

  2011cites this paper
• An abnormal nonhyperdiploid karyotype is a significant adverse prognostic factor for multiple myeloma in the bortezomib era

  2010cites this paper
• Supervivencia a los 3 años de pacientes con mieloma múltiple.

  2006cites this paper
• The role of the bone marrow microenvironment in multiple myeloma.

  2005cites this paper
• MDS‐type abnormalities within myeloma signature karyotype (MM‐MDS): only 13% 1‐year survival despite tandem transplants

  2003cites this paper
• A high bone marrow plasma cell labeling index in stable plateau-phase multiple myeloma is a marker for early disease progression and death.

  2001cites this paper
• Immunophenotypic aberrations, DNA content, and cell cycle analysis of plasma cells in patients with myeloma and monoclonal gammopathies.

  2000cites this paper
• CD138/syndecan-1: a useful immunohistochemical marker of normal and neoplastic plasma cells on routine trephine bone marrow biopsies.

  1999cites this paper
• Multiple myeloma in younger patients: the role of age as prognostic factor

  1998cites this paper
• Prognostic value of numerical chromosome aberrations in multiple myeloma: A FISH analysis of 15 different chromosomes.

  1998cites this paper
• DNA cell content studies in multiple myeloma.

  1996cites this paper
• A New Staging System for Multiple Myeloma Based on the Number of S-Phase Plasma Cells

  1995cites this paper
• A new staging system for multiple myeloma based on the number of S-phase plasma cells.

  1995cites this paper
• Immunophenotype and DNA cell content in multiple myeloma.

  1995cites this paper
• [The treatment of multiple myeloma].

  1994cites this paper
• Cyclophosphamide (3.6 g/m2) therapy with G-CSF support for resistant myeloma.

  1994cites this paper
• Prognostic factors in myeloma: what they tell us about the pathophysiology of the disease.

  1994cites this paper
• Multiple myeloma: an overview of diagnosis and management.

  1994cites this paper
• An evaluation of five different methods for estimating proliferation in human colorectal adenocarcinomas.

  1994cites this paper
• Plasma cell labeling index and β2-microglobulin predict survival independent of thymidine kinase and C-reactive protein in multiple myeloma

  1993cites this paper
• Plasma cell labeling index and beta 2-microglobulin predict survival independent of thymidine kinase and C-reactive protein in multiple myeloma.

  1993cites this paper
• Standard chemotherapy for myelomatosis: an area of great controversy.

  1992cites this paper
• Will a tumor metastasize? Quantitate, semi-quantitate or pseudo-quantitate?

  1992cites this paper
• No correlation between response and survival in patients with multiple myeloma treated with vincristine, melphalan, cyclophosphamide, and prednisone

  1991cites this paper
• How malignant is malignant? A brief review of the microscopic assessment of human neoplasms, and the prediction of whether they will metastasize and kill

  1991cites this paper
• Lymphoproliferations in the Bone Marrow

  1990cites this paper
• The clinical assessment of proliferation and growth in human tumours: Evaluation of methods and applications as prognostic variables

  1990cites this paper
• Kappa/lambda ratio on peripheral blood lymphocytes and bone marrow plasma cell labeling index in monoclonal gammopathies.

  1990cites this paper
• The plasma cell labeling index: a valuable tool in primary systemic amyloidosis.

  1989cites this paper